---
figid: PMC9537356__pore-28-1610694-g009
figtitle: On-Target Side Effects of Targeted Therapeutics of Cancer
organisms:
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC9537356
filename: pore-28-1610694-g009.jpg
figlink: /pmc/articles/PMC9537356/figure/F9/
number: F9
caption: Schematic presentation of BRAF inhibitor effect on the growth factor receptor
  (GFR) signaling pathways of precursor cancer cells where carcinogenesis iniciated
  by RAS mutation (KRAS/NRAS/HRAS). BRAF inhibitor induces CRAF/BRAF homo- and heterodimerisation
  and activates the RAF-MEK ERK mitogenic signaling pathway. Arrow thickness represents
  signal intensities.
papertitle: On-Target Side Effects of Targeted Therapeutics of Cancer.
reftext: József Tímár, et al. Pathol Oncol Res. 2022;28:1610694.
year: '2022'
doi: 10.3389/pore.2022.1610694
journal_title: Pathology and Oncology Research
journal_nlm_ta: Pathol Oncol Res
publisher_name: Frontiers Media S.A.
keywords: immunotherapy | target therapy | bone therapy | angiogenesis inhibitor |
  side effect | pathomechanism
automl_pathway: 0.9288357
figid_alias: PMC9537356__F9
figtype: Figure
redirect_from: /figures/PMC9537356__F9
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9537356__pore-28-1610694-g009.html
  '@type': Dataset
  description: Schematic presentation of BRAF inhibitor effect on the growth factor
    receptor (GFR) signaling pathways of precursor cancer cells where carcinogenesis
    iniciated by RAS mutation (KRAS/NRAS/HRAS). BRAF inhibitor induces CRAF/BRAF homo-
    and heterodimerisation and activates the RAF-MEK ERK mitogenic signaling pathway.
    Arrow thickness represents signal intensities.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAPGEF5
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - gfr
  - nac
  - Dsor1
  - Mtk
  - Erk7
  - rl
---
